H.C. Wainwright analyst Raghuram Selvaraju reiterated his Sell rating on shares of Ironwood Pharmaceuticals (IRWD) after partner Allergan (AGN) indicated with its quarterly earnings report that it expects future revenue growth for Linzess to be in the low- to mid-single digits. He also believes that Ironwood's own financials for the third quarter may prove even more disappointing due to the company's history of poor operational expense control, Selvaraju added. He keeps a $12.50 price target on Ironwood shares ahead of its quarterly report, due on November 6.